Abstract:Abstract Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells. Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR). More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies. In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions. Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016. To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies. BTK inhibition has molecular effects beyond its classic role in BCR signaling. These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches. Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment. As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors. Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses. In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.

Progression of Bruton tyrosine kinase (BTK) inhibitor in B-cell lymphoma

Effects of BTK Signalling in Pathogenic Microorganism Infections

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia

A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications

The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas

Bruton's Tyrosine Kinase Ablation Inhibits B Cell Responses and Antibody Production for the Prevention of Chronic Rejection in Cardiac Transplantation.

Role of Bruton’s tyrosine kinase in B cells and malignancies

Targeting Bruton's tyrosine kinase in B cell malignancies

Burgeoning Data on BTK Inactivating Mutations in Lymphomagenesis and Therapeutic Resistance

Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy

Advances in the treatment of mantle cell lymphoma with BTK inhibitors

Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib

The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

BTK inhibitors: past, present, and future

Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment

Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis

New means and challenges in the targeting of BTK